Literature DB >> 2555391

Enumeration of viral antigen-reactive helper T lymphocytes in human peripheral blood by limiting dilution for analysis of viral antigen-reactive T-cell pools in virus-seropositive and virus-seronegative individuals.

K A Clouse1, P W Adams, C G Orosz.   

Abstract

A limiting-dilution analysis technique was developed which enumerates human T cells with the capacity to secrete T-cell growth factors such as interleukin 2 after contact with herpes simplex virus type 1 (HSV-1) or cytomegalovirus (CMV) antigens (operationally defined as virus-reactive helper T cells [HTL]). By using this limiting-dilution analysis technique, the peripheral blood of HSV-seropositive individuals was analyzed for the frequency of HSV antigen-reactive HTL and for the ability either to proliferate or to secrete detectable T-cell growth factors in conventional HSV antigen-stimulated lymphocyte cultures. We found that the magnitudes of the latter two responses did not correlate directly with the frequency estimates of HSV antigen-reactive HTL. The study was expanded to analyze both HSV and CMV reactivities within individuals. Those who were seropositive for HSV or CMV were found to have relatively high HTL frequencies for the viral antigens to which they were sensitized. However, those who were seronegative for one of the viruses often had HTL reactive with that virus in their peripheral blood. These latter HTL frequencies were highly variable and ranged from undetectable to quite prominent, even within the same individual at different times. In general, it was found that viral antigen-reactive serologic activity does not necessarily reflect the status of viral antigen-reactive cell-mediated immunity in humans and that viral antigen-induced T-cell responses may be unexpectedly complex, rather than absent, in individuals who are seronegative for a particular virus.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2555391      PMCID: PMC267016          DOI: 10.1128/jcm.27.10.2316-2323.1989

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  43 in total

1.  Stimulation of human lymphocytes by Herpes simplex virus antigens.

Authors:  S E Starr; S A Karatela; S L Shore; A Duffey; A J Nahmias
Journal:  Infect Immun       Date:  1975-01       Impact factor: 3.441

2.  T-cell-mediated cytotoxicity against herpes simplex virus-infected target cells.

Authors:  K Pfizenmaier; A Starzinski-Powitz; M Röllinghoff; D Falks; H Wagner
Journal:  Nature       Date:  1977-02-17       Impact factor: 49.962

3.  Cell-mediated immunity to herpes simplex virus in man.

Authors:  A S Russell
Journal:  J Infect Dis       Date:  1974-02       Impact factor: 5.226

Review 4.  Infection with herpes-simplex viruses 1 and 2. 3.

Authors:  A J Nahmias; B Roizman
Journal:  N Engl J Med       Date:  1973-10-11       Impact factor: 91.245

5.  Proteins specified by herpes simplex virus. V. Purification and structural proteins of the herpesvirion.

Authors:  P G Spear; B Roizman
Journal:  J Virol       Date:  1972-01       Impact factor: 5.103

6.  The glomerular permeability determined by dextran clearance using Sephadex gel filtration.

Authors:  C E Mogensen
Journal:  Scand J Clin Lab Invest       Date:  1968       Impact factor: 1.713

Review 7.  T lymphocyte interaction with viruses and virus-infected tissues.

Authors:  J F Woodruff; J J Woodruff
Journal:  Prog Med Virol       Date:  1975

8.  Cell-mediated immune responses in recurrent herpesvirus infections. I. Lymphocyte proliferation assay.

Authors:  C Lopez; R J O'Reilly
Journal:  J Immunol       Date:  1977-03       Impact factor: 5.422

9.  Lymphocyte transformation and interferon production in human mononuclear cell microcultures for assay of cellular immunity to herpes simplex virus.

Authors:  S Haahr; L Rasmussen; T C Merigan
Journal:  Infect Immun       Date:  1976-07       Impact factor: 3.441

10.  Specific immunity after congenital or neonatal infection with cytomegalovirus or herpes simplex virus.

Authors:  A R Hayward; M J Herberger; J Groothuis; M R Levin
Journal:  J Immunol       Date:  1984-11       Impact factor: 5.422

View more
  6 in total

1.  Determination of antigen-specific memory/effector CD4+ T cell frequencies by flow cytometry: evidence for a novel, antigen-specific homeostatic mechanism in HIV-associated immunodeficiency.

Authors:  S L Waldrop; C J Pitcher; D M Peterson; V C Maino; L J Picker
Journal:  J Clin Invest       Date:  1997-04-01       Impact factor: 14.808

2.  Severe genital herpes infections in HIV-infected individuals with impaired herpes simplex virus-specific CD8+ cytotoxic T lymphocyte responses.

Authors:  C M Posavad; D M Koelle; M F Shaughnessy; L Corey
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-16       Impact factor: 11.205

3.  Cytomegalovirus viral load and virus-specific immune reconstitution after peripheral blood stem cell versus bone marrow transplantation.

Authors:  Abraham Guerrero; Stanley R Riddell; Jan Storek; Terry Stevens-Ayers; Barry Storer; John A Zaia; Stephen Forman; Robert S Negrin; Thomas Chauncey; William Bensinger; Michael Boeckh
Journal:  Biol Blood Marrow Transplant       Date:  2011-05-20       Impact factor: 5.742

4.  High frequency of CD8+ cytotoxic T-lymphocyte precursors specific for herpes simplex viruses in persons with genital herpes.

Authors:  C M Posavad; D M Koelle; L Corey
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

5.  Divergent patterns of progression to AIDS after infection from the same source: human immunodeficiency virus type 1 evolution and antiviral responses.

Authors:  S L Liu; T Schacker; L Musey; D Shriner; M J McElrath; L Corey; J I Mullins
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

6.  Tegument-specific, virus-reactive CD4 T cells localize to the cornea in herpes simplex virus interstitial keratitis in humans.

Authors:  D M Koelle; S N Reymond; H Chen; W W Kwok; C McClurkan; T Gyaltsong; E W Petersdorf; W Rotkis; A R Talley; D A Harrison
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.